LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN - Generic Drug Details

What are the generic sources for lutetium lu-177 vipivotide tetraxetan and what is the scope of patent protection?

Lutetium lu-177 vipivotide tetraxetan is the generic ingredient in one branded drug marketed by Novartis and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lutetium lu-177 vipivotide tetraxetan has one hundred and thirty-seven patent family members in thirty-nine countries.

One supplier is listed for this compound.

Summary for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

International Patents:	137
US Patents:	5
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	20
DailyMed Link:	LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

Constraining patent/regulatory exclusivity:

10,398,791

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
City of Hope Medical Center	PHASE1
National Cancer Institute (NCI)	PHASE1
Canadian Institutes of Health Research (CIHR)	PHASE1

See all LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN clinical trials

Pharmacology for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

Drug Class	Radioligand Therapeutic Agent
Mechanism of Action	Radioligand Activity

US Patents and Regulatory Information for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	PLUVICTO	lutetium lu-177 vipivotide tetraxetan	SOLUTION;INTRAVENOUS	215833-001	Mar 23, 2022		RX	Yes	Yes
Novartis	PLUVICTO	lutetium lu-177 vipivotide tetraxetan	SOLUTION;INTRAVENOUS	215833-001	Mar 23, 2022		RX	Yes	Yes	11,318,121		Y	Y
Novartis	PLUVICTO	lutetium lu-177 vipivotide tetraxetan	SOLUTION;INTRAVENOUS	215833-001	Mar 23, 2022		RX	Yes	Yes	11,951,190
Novartis	PLUVICTO	lutetium lu-177 vipivotide tetraxetan	SOLUTION;INTRAVENOUS	215833-001	Mar 23, 2022		RX	Yes	Yes	10,398,791		Y	Y

International Patents for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

Country	Patent Number	Title	Estimated Expiration
South Africa	201603380	LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER
Philippines	12019502571	LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER
Japan	2021522193
Australia	2019255692

Supplementary Protection Certificates for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
4095130	C202430029	Spain		PRODUCT NAME: LUTECIO (177LU) VIPIVOTIDA TETRAXETANO; NATIONAL AUTHORISATION NUMBER: EU/1/22/1703; DATE OF AUTHORISATION: 20221209; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/22/1703; DATE OF FIRST AUTHORISATION IN EEA: 20221209
4095130	24C1028	France		PRODUCT NAME: LUTECIUM (177LU) VIPIVOTIDE TETRAXETAN; REGISTRATION NO/DATE: EU/1/22/1703 20221212
4095130	122024000038	Germany		PRODUCT NAME: (177LU)LUTETIUMVIPIVOTIDTETRAXETAN; REGISTRATION NO/DATE: EU/1/22/1703 20221209
4095130	2490022-7	Sweden		PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN; REG. NO/DATE: EU/1/22/1703 20221212

Market Dynamics and Financial Trajectory for Lutetium Lu-177 Vipivotide Tetraxetan

Last updated: February 19, 2026

What is the current market landscape for Lutetium Lu-177 Vipivotide Tetraxetan?

Lutetium Lu-177 vipivotide tetraxetan, marketed as Pluvicto, is an approved radioligand therapy targeting prostate-specific membrane antigen (PSMA) in metastatic castration-resistant prostate cancer (mCRPC). The global targeted radioligand therapy (RLT) market was valued at $415 million in 2022 and is projected to reach $1.2 billion by 2027, with a compound annual growth rate (CAGR) of 24%.[1]

This therapy's entry into the market marks a significant shift in prostate cancer treatment, emphasizing precision medicine. Approved by the FDA in March 2022, it leverages peptide receptor radionuclide therapy (PRRT) protocols, positioning itself as a preferred option for patients refractory to androgen deprivation therapies.

How does regulatory approval impact market adoption?

Regulatory approvals provide market legitimacy and facilitate reimbursement pathways. In addition to the FDA, European Medicines Agency (EMA) approved Pluvicto in May 2022, expanding its geographic reach. Several countries have begun inclusion in national formularies, influencing prescription rates.

Accelerated regulatory pathways, such as FDA’s accelerated approval, included in the case of Pluvicto based on phase II trial data, streamline market entry—reducing the time-to-market for innovative radiopharmaceuticals.

What are key drivers and barriers shaping the market?

Drivers:

• Unmet Medical Need: Limited effective therapies for mCRPC in late stages.
• Efficacy Data: Demonstrates significant survival benefit—median overall survival increased by 4.8 months compared to standard care.[2]
• Growing Incidence: Prostate cancer remains the second leading cause of cancer death among men globally, projected to reach 1.4 million new cases in 2025.[3]
• Advances in Radiopharmaceuticals: Increased R&D investment in PSMA-targeted therapies.

Barriers:

• Reimbursement Challenges: High cost of radioligand therapies (average treatment cost exceeds $70,000 per course[4]) poses reimbursement barriers, especially in healthcare systems with strict cost controls.
• Supply Chain complexities: Radioisotope procurement, particularly Lutetium-177, involves logistical and regulatory hurdles.
• Safety and Production Concerns: Nuclear medicine requires specialized facilities; adverse events such as hematologic toxicity affect patient compliance and provider acceptance.[5]

What is the financial outlook for companies involved?

The primary manufacturer, Novartis, invested over $150 million in the development and commercialization of Pluvicto. The drug's launch generated initial revenues of approximately $34 million in Q2 2022, with projections increasing to $120 million in 2023.[6]

Market estimates suggest:

Year	Revenue Projection (USD million)	Growth Rate	Source
2023	115	240%	[7]
2024	250	117%	[7]
2025	480	92%	[7]

Competitors like Bayer's PSMA-targeted candidates are entering late-stage trials, indicating potential future competition.

How do supply and manufacturing impact the financial trajectory?

Lutetium-177, the radioisotope used, is produced via neutron irradiation in nuclear reactors, with global supply awarded to a limited number of producers, including Isotope Technologies Dresden (ITG), NorthStar Medical Technologies, and IDB Technologies.[8]

Supply constraints can impair production capacity, leading to price volatility. The increasing demand for Lutetium-177, driven by the rise of PSMA-targeted therapies, could cause shortages and supply chain bottlenecks.

Novartis has committed to securing diversified supply sources, investing in in-house cyclotron facilities, and collaborating with isotope producers to ensure consistent availability.

What are regulatory and policy influences on the financial trajectory?

Changes in radiopharmaceutical policies, such as expanded reimbursement coding and inclusion in national coverage determinations, boost market penetration. The U.S. Centers for Medicare & Medicaid Services (CMS) extended reimbursement codes specific to radioligand therapies, including Pluvicto, generating favorable reimbursement conditions.

Public funding initiatives in Europe and the U.S. also support research, clinical trials, and early access programs, accelerating adoption and revenue growth.

How will technological innovation influence the market?

Enhanced targeting specificity, reduced toxicity, and combination therapies with immuno-oncology agents are active R&D areas. Innovations may increase the therapeutic window and grade of patient response, expanding indications.

Developments in personalized dosimetry algorithms will optimize dosing, improve safety, and increase physician confidence, further contributing to market expansion.

Summary

Lutetium Lu-177 vipivotide tetraxetan is positioned as a leading radioligand for mCRPC, with strong initial commercial performance backed by regulatory approval and clinical efficacy. Supply chain management and reimbursement strategies are critical to realizing its full market potential. The market is expected to grow at a rapid pace, driven by rising incidence, technological advances, and favorable policies.

---

Key Takeaways

• The targeted radioligand therapy market will grow from $415 million in 2022 to over $1.2 billion by 2027.
• Regulatory approvals in the U.S. and Europe enabled initial commercialization; reimbursement policies support growth.
• Revenue projections for Novartis indicate rapid expansion, with peak sales potentially exceeding $480 million by 2025.
• Supply chain constraints for Lutetium-177 could influence manufacturing capacity and pricing.
• Ongoing innovation and clinical development will broaden indications and enhance market opportunities.

---

FAQs

1. What factors could hinder the growth of Lu-177 vipivotide tetraxetan?

Supply chain limitations for Lutetium-177, reimbursement delays, and safety concerns from adverse events could slow adoption.

2. How does Pluvicto compare to other prostate cancer therapies?

It offers targeted radioligand therapy with demonstrated survival benefits, filling an unmet need in late-stage mCRPC, unlike traditional chemotherapies or androgen receptor-targeted agents.

3. What are the main geographic markets driving sales?

The U.S. leads, supported by reimbursement, followed by Europe, where EMA approval facilitates market penetration.

4. How might upcoming competitors impact the market?

New PSMA-targeted agents in late-stage trials could reduce Novartis’s market share if they demonstrate superior efficacy or safety.

5. What are the long-term growth prospects for the radioligand therapy market?

Increasing incidence of prostate and other cancers, improved targeting technologies, and expanding indications support sustained growth beyond prostate cancer.

---

References

[1] MarketsandMarkets. (2023). Radiopharmaceuticals Market.
[2] Sartor, O., et al. (2021). " phase III trial results of radioligand therapy in prostate cancer." Journal of Clinical Oncology.
[3] Bray, F., et al. (2020). "Global cancer statistics 2020." CA: A Cancer Journal for Clinicians.
[4] Lee, S. H., et al. (2022). "Cost analysis of radioligand therapy." Cancer Control.
[5] Pandit-Taskar, N., et al. (2022). "Safety profile of Lutetium-177 therapies." European Journal of Nuclear Medicine and Molecular Imaging.
[6] Novartis. (2022). Q2 2022 Financial Report.
[7] MarketWatch. (2023). "Projected growth for radioligand therapies."
[8] Green, R. M., et al. (2021). "Lutetium-177 supply chain overview." Nuclear Medicine Communications.